Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of... Purpose Patients receiving platinum-based chemotherapy are in patients with lung cancer receiving platinum-based chemo- at high risk of chemotherapy-induced nausea and vomiting therapy, across the acute, delayed, and overall phases and (CINV), a distressing side effect of treatment. This post-hoc throughout multiple cycles. As a highly effective oral combi- subgroup analysis of two pivotal trials evaluated the efficacy nation antiemetic agent administered as a single dose once per of NEPA in preventing CINV in subsets of patients with lung cycle, NEPA may offer a convenient, simplified prophylactic cancer who received cisplatin or carboplatin. antiemetic. Methods In each study, the efficacy endpoints complete re- . . . sponse (CR; defined as no emetic episodes and no rescue Keywords Lung cancer Cisplatin Carboplatin medication) and no significant nausea (NSN; defined as a Chemotherapy-induced nausea and vomiting (CINV) NEPA score of < 25 mm on a visual analog scale of 0–100 mm) during the acute (0–24 h), delayed (25–120 h), and overall (0–120 h) phases post-chemotherapy in cycle 1 (study 1) Introduction and cycles 1–4 (study 2) were assessed. Safety was evaluated by recording treatment-emergent adverse events (AEs) and Lung cancer is the most common cancer worldwide, with treatment-related AEs. an estimated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic

Loading next page...
 
/lp/springer_journal/preventing-chemotherapy-induced-nausea-and-vomiting-in-patients-with-EHGaAzQ4NT
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
D.O.I.
10.1007/s00520-017-3936-9
Publisher site
See Article on Publisher Site

Abstract

Purpose Patients receiving platinum-based chemotherapy are in patients with lung cancer receiving platinum-based chemo- at high risk of chemotherapy-induced nausea and vomiting therapy, across the acute, delayed, and overall phases and (CINV), a distressing side effect of treatment. This post-hoc throughout multiple cycles. As a highly effective oral combi- subgroup analysis of two pivotal trials evaluated the efficacy nation antiemetic agent administered as a single dose once per of NEPA in preventing CINV in subsets of patients with lung cycle, NEPA may offer a convenient, simplified prophylactic cancer who received cisplatin or carboplatin. antiemetic. Methods In each study, the efficacy endpoints complete re- . . . sponse (CR; defined as no emetic episodes and no rescue Keywords Lung cancer Cisplatin Carboplatin medication) and no significant nausea (NSN; defined as a Chemotherapy-induced nausea and vomiting (CINV) NEPA score of < 25 mm on a visual analog scale of 0–100 mm) during the acute (0–24 h), delayed (25–120 h), and overall (0–120 h) phases post-chemotherapy in cycle 1 (study 1) Introduction and cycles 1–4 (study 2) were assessed. Safety was evaluated by recording treatment-emergent adverse events (AEs) and Lung cancer is the most common cancer worldwide, with treatment-related AEs. an estimated

Journal

Supportive Care in CancerSpringer Journals

Published: Oct 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off